Cubist hits new high on top-line Phase III antibiotic data
This article was originally published in Scrip
Executive Summary
Cubist Pharmaceuticals's stock reached a new high on 25 November after the company announced top-line results from a Phase III study for its intravenous antibiotic ceftolozane/tazobactam (CXA-201) in the treatment of complicated urinary tract infections (cUTI), including statistical superiority over levofloxacin.